ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Alfuzosin

Alpha-Adrenoreceptor Antagonists

GB MHRACA Health Canada

Drug class: Alpha-Adrenoreceptor Antagonists
Availability: See label
Routes: Oral
Markets covered: 2
Products on record: 10

Overview

Alfuzosin is an active pharmaceutical ingredient in the Alpha-Adrenoreceptor Antagonists group (G04CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	8	May 22, 2026
CA Canada	Health Canada	2	March 22, 2025

GBUnited Kingdom· MHRA

8 products

Uses

GBOfficial regulatory label· revised September 1, 2025[1]

Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).

How to take

GBOfficial regulatory label

CACanada· Health Canada

2 products

Uses

CAOfficial regulatory label· revised March 22, 2025[2]

…….............. ………........... …….............. …………............. ……………................ …............................ …………......................... 14 ACTION AND CLINICAL PHARMACOLOGY…......................... …….......... 20 SPECIAL HANDLING INSTRUCTION…………………………..
21 DOSAGE FORMS, COMPOSITION AND PACKAGING……..... …....... …............. ……………...... …………….. …………………………............ …………………………..... ……… 40 ALFUZOSIN Product Monograph Page 3 of 42 PrALFUZOSIN Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg House Standard PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength All Nonmedicinal Ingredients Oral Prolonged-Release Tablets 10 mg Core Tablet contains: Hypromellose, Hydrogenated Vegetable oil, Povidone, Calcium Hydrogen Phosphate Anhydrous, Carbomer, Silica colloidal Anhydrous and Magnesium Stearate Film coat contains: Hypromellose, Propylene Glycol and Titanium Dioxide.
INDICATIONS AND CLINICAL USE ALFUZOSIN (alfuzosin hydrochloride) is indicated for:  Benign Prostatic Hyperplasia ALFUZOSIN is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).  Acute Urinary Retention ALFUZOSIN is indicated as adjunctive therapy with urethral catheterization for Acute Urinary Retention related to BPH and management following catheter removal.

Drug interactions

Known interactions involving Alfuzosin. Select one for details. This list is informational and not a complete interaction checker.

Amiodarone Amisulpride Amprenavir Anagrelide Arsenic Trioxide Atazanavir Bedaquiline Bepridil Boceprevir Cabozantinib Ceritinib Chloroquine Cisapride Citalopram Clarithromycin Clozapine Cobicistat Crizotinib Darunavir Delavirdine Disopyramide Dofetilide Dolasetron Dronedarone Droperidol Efavirenz Erythromycin Escitalopram Fingolimod Fosamprenavir Gatifloxacin Grepafloxacin Halofantrine Haloperidol Hydroxychloroquine Ibutilide Idelalisib Iloperidone Indinavir Itraconazole Ivabradine Ivosidenib Ketoconazole Lefamulin Lonafarnib Lumefantrine Macimorelin Mesoridazine Methadone Mifepristone Moxifloxacin Nefazodone Nelfinavir Nilotinib Osimertinib Ozanimod Panobinostat Papaverine Pasireotide Pimozide Posaconazole Procainamide Quinidine Ribociclib Ritonavir Saquinavir Selpercatinib Siponimod Sotalol Sparfloxacin Telaprevir Telithromycin Thioridazine Toremifene Troleandomycin Tucatinib Vandetanib Vemurafenib Voriconazole Ziprasidone Abametapir Abarelix Abiraterone Acebutolol Adenosine Albuterol Alfentanil Alprazolam Amifostine Amitriptyline Amobarbital Amoxapine Apalutamide Apomorphine Apraclonidine Aprepitant Arformoterol Aripiprazole Asenapine Astemizole Atenolol Atomoxetine Avanafil Azithromycin Baclofen Benazepril Bendroflumethiazide Benzhydrocodone Benzthiazide Betaxolol Bicalutamide Bisacodyl Bisoprolol Bosutinib Brexpiprazole Brimonidine Buprenorphine Bupropion Buspirone Butabarbital Butalbital Butorphanol Canagliflozin Captopril Cariprazine Carisoprodol Carteolol Carvedilol Castor Oil Chloramphenicol Chlordiazepoxide Chlormezanone Chlorothiazide Chlorphenesin Chlorpromazine Chlorthalidone Chlorzoxazone Cilostazol Ciprofloxacin Clobazam Clofazimine Clomipramine Clonazepam Clorazepate Clotrimazole Codeine Conivaptan Cyclobenzaprine Cyclosporine Dabrafenib Dalfopristin Danazol Dapagliflozin Dasatinib Daunorubicin Deferasirox Degarelix Desipramine Deutetrabenazine Dexmedetomidine Dezocine Diazepam Dichloralphenazone Dihydrocodeine Diltiazem Dimenhydrinate Diphenhydramine Donepezil Doxazosin Doxepin Doxorubicin Dronabinol Duvelisib Empagliflozin Enalapril Encorafenib Entrectinib Enzalutamide Epirubicin Epoprostenol Ertugliflozin Esmolol Ethanol Etravirine Ezogabine Famotidine Fedratinib Fenoldopam Fentanyl Flecainide Fluconazole Fluoxetine Fluphenazine Flurazepam Flutamide Formoterol Fosaprepitant Foscarnet Fosinopril Fostamatinib Fostemsavir Galantamine Gemifloxacin Gilteritinib Glasdegib Glycerin Goserelin Granisetron Guanfacine Halazepam Halothane Histrelin Hydrochlorothiazide Hydrocodone Hydroflumethiazide Hydromorphone Hydroxyzine Idarubicin Iloprost Imatinib Imipramine Indacaterol Indapamide Inotuzumab Ozogamicin Isavuconazonium Isocarboxazid Isoetharine Isoproterenol Ivacaftor Labetalol Lactitol Lactulose Lapatinib Larotrectinib Lenvatinib Letermovir Leuprolide Levobetaxolol Levobunolol Levodopa

Showing 240 of 495. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL002891074 · revised September 1, 2025
[2]Health Canada (DPD) · 02447576 · revised March 22, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.